uPAR Antibody (10G7): sc-13522

uPAR Antibody (10G7) is a mouse monoclonal IgG antibody that detects uPAR of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). uPAR monoclonal antibody (10G7) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Urokinase plasminogen activator receptor (uPAR), also known as CD87, is a glycoprotein I-anchored surface receptor that plays a critical role in the regulation of pericellular proteolysis and is essential for processes such as wound healing and tissue remodeling. Located on the cell surface, uPAR interacts with urokinase plasminogen activator (uPA) to convert plasminogen into plasmin, a serine protease that facilitates the breakdown of fibrin in blood clots. This function is particularly important in the context of tumor biology, as uPAR and uPA are often overexpressed in various cancers, promoting tumor invasion and metastasis. The signaling cascade initiated by uPA binding to uPAR involves key downstream effectors such as Ras, MEK, ERK, and MLCK, which collectively enhance cellular migration in an integrin-selective manner. Given uPAR′s significant role in cancer progression and tissue repair, uPAR serves as a valuable biomarker and therapeutic target, making uPAR monoclonal antibody (10G7) an essential tool for researchers studying these critical biological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

uPAR Antibody (10G7) References:

1. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.  |  Nguyen, DH., et al. 1999. J Cell Biol. 146: 149-64. PMID: 10402467
2. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.  |  Aguirre Ghiso, JA., et al. 1999. Eur J Biochem. 263: 295-304. PMID: 10406935
3. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.  |  Solberg, H., et al. 1992. Eur J Biochem. 205: 451-8. PMID: 1374026
4. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.  |  Roldan, AL., et al. 1990. EMBO J. 9: 467-74. PMID: 1689240
5. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.  |  Behrendt, N., et al. 1990. J Biol Chem. 265: 6453-60. PMID: 2156852
6. Tissue-type plasminogen activator: a new fibrinolytic agent.  |  Milligan, KS. 1987. Heart Lung. 16: 69-74. PMID: 3098703
7. Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease.  |  Cheng, Y., et al. 2022. EBioMedicine. 75: 103758. PMID: 34933179
8. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.  |  Qin, L., et al. 2022. Sci Adv. 8: eabn3774. PMID: 35613265
9. The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease.  |  Zhu, K., et al. 2023. Sci Transl Med. 15: eabq6492. PMID: 37729431
10. Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.  |  Hamada, M., et al. 2024. Biomedicines. 12: PMID: 38927374
11. Factor XII signaling via uPAR-integrin β1 axis promotes tubular senescence in diabetic kidney disease.  |  Elwakiel, A., et al. 2024. Nat Commun. 15: 7963. PMID: 39261453
12. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.  |  Prentice, CR., et al. 1993. Br J Haematol. 83: 276-81. PMID: 8457476

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-uPAR Antibody (10G7) has 16 citations in a variety of scientific publications.

Primary antibodies like Anti-uPAR Antibody (10G7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

uPAR Antibody (10G7) Specifications

Alternate Product Name: CD87

Product Clone Name: 10G7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG

Amino Acids:

Epitope Target: uPAR

Epitope Species: human

Product Reactivity/Detection: uPAR

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), FCM, ELISA

Vialing Information: Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 16 citations in various scientific publications

Available Conjugates/Forms for uPAR Antibody (10G7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin